Stan Smith Buys 75,000 Shares of MAIA Biotechnology (NYSEAMERICAN:MAIA) Stock

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Stan Smith acquired 75,000 shares of the stock in a transaction on Monday, June 1st. The stock was bought at an average price of $1.34 per share, with a total value of $100,500.00. Following the transaction, the director directly owned 1,519,178 shares of the company’s stock, valued at approximately $2,035,698.52. The trade was a 5.19% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

MAIA Biotechnology Stock Performance

Shares of MAIA stock opened at $1.43 on Thursday. MAIA Biotechnology, Inc. has a fifty-two week low of $0.87 and a fifty-two week high of $3.19. The stock has a 50 day moving average price of $1.32 and a two-hundred day moving average price of $1.53. The company has a market capitalization of $86.94 million, a P/E ratio of -2.13 and a beta of 0.23.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.04. As a group, equities analysts predict that MAIA Biotechnology, Inc. will post -0.52 earnings per share for the current year.

Hedge Funds Weigh In On MAIA Biotechnology

Several hedge funds have recently made changes to their positions in MAIA. Corsair Capital Management L.P. purchased a new position in shares of MAIA Biotechnology during the first quarter valued at approximately $140,000. Jane Street Group LLC purchased a new position in shares of MAIA Biotechnology during the fourth quarter valued at approximately $120,000. Geode Capital Management LLC increased its stake in shares of MAIA Biotechnology by 9.5% during the fourth quarter. Geode Capital Management LLC now owns 296,740 shares of the company’s stock valued at $454,000 after buying an additional 25,684 shares during the period. Ritholtz Wealth Management purchased a new position in shares of MAIA Biotechnology during the fourth quarter valued at approximately $35,000. Finally, Marshall Wace LLP purchased a new position in shares of MAIA Biotechnology during the second quarter valued at approximately $29,000. 5.65% of the stock is owned by hedge funds and other institutional investors.

About MAIA Biotechnology

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.